Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder that leads to weakness in the skeletal muscles, which can affect various parts of the body, including the eyes, face, and limbs.
Efgartigimod for Early Treatment of Generalized Myasthenia Gravis
We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of myasthenia gravis?
- Are you currently pregnant or breastfeeding?
- Have you received any immunosuppressive treatment for myasthenia gravis before?
- Have you had any live vaccines in the past month?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Bellvitge University Hospital
Neurology
L'Hospitalet de Llobregat, Spain
Sponsor: Bellvitge University Hospital
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.